logo
Plus   Neg
Share
Email

Silgan Holdings Q1 Profit Rises

Silgan Holdings Inc. (SLGN) Thursday reported an increase in profit for the first quarter, due mainly to higher revenues.

The Stamford, Connecticut-based company reported first-quarter net profit of $32.8 million or $0.47 per share, compared to $26.1 million or $0.37 per share last year.

Adjusted earnings for the quarter rose to $0.50 per share from $0.41 per share in the prior-year quarter. On average, 12 analysts polled by Thomson Reuters expected the company to earn $0.46 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenues for the quarter grew 9.3 percent to $768.4 million from $703.1 million in the prior-year quarter. Nine analysts had a consensus revenue estimate of $785.92 million for the quarter.

Looking ahead, the company expects second-quarter adjusted earnings of $0.55 to $0.60 per share. Analysts currently expect the company to earn $0.57 per share for the quarter.

The company confirmed its full-year 2012 earnings guidance in the range of $2.80 to $2.90 per share. Analysts currently expect earnings of $2.88 per share for the year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT